홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Alprostadil

HCID 5280723
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
745-65-3
표준 SMILES
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O
InChIKey
GMVPRGQOIOIIMI-DWKJAMRDSA-N
분자식
C20H34O5
평균 분자량
354.5 g/mol
단동위원소 질량
354.24062418

개요

Prostaglandin E1 is a prostaglandins E. It has a role as a vasodilator agent, an anticoagulant, a platelet aggregation inhibitor and a human metabolite. It is a conjugate acid of a prostaglandin E1(1-).

이름 및 식별자

우선 이름
Alprostadil
IUPAC
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
영어명
Prostaglandin E1
분자식
C20H34O5
분자량
354.48

이름 및 동의어

alprostadilProstaglandin E1745-65-3PGE1CaverjectEdexMuseAlprostadilumBefarProstin VR PediatricVitarosPrink
이름 더 보기
Alprostadil (PGE1)Prost-13-en-1-oic acidProstaglandine E1PGElLiplePalux
PGE-1Prostavasin(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acidCaverject ImpulsePGE1alphaDTXSID9022578Lipo PGE1Prostaglandin E1alpha

데이터베이스 식별자

CAS
745-65-3
PubChem CID
5280723
DTXSID
DTXSID9022578
ChEMBL
CHEMBL495
ChEBI
CHEBI:15544
UNII
F5TD010360
EC Number
212-017-2
Nikkaji
J3.319G

물성

구조 계산 물성

XLogP
3.2
극성 표면적
94.8 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
5
회전 가능 결합 수
13
무거운 원자 수
25
형식 전하
0
복잡도
432

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
LipidsFatty Acyls [FA] -> Eicosanoids [FA03] -> Prostaglandins [FA0301]
LogP3.20
Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2건

115-116 °C

115 - 116 °C

Physical DescriptionSolid
Dissociation Constants · 2건

4.87

4.85 (at 25 °C)

Collision Cross Section · 2건

190.6 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Calculation: Single Field; Dataset: Oxylipins]

181.94 Ų [M-H2O-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

물리화학적 성질

녹는점
115 · 115-116 °C
끓는 점
407.69 °C · 407.69°C (rough estimate)
밀도
1.0458 · 1.0458 (rough estimate)
굴절률
1.612 · 1.6120 (estimate)
저장 조건
-20 °C · -20°C
용해도
1 mg/mL · 에탄올: 1mg/mL
산도 계수 (pKa)
4.85 · pKa 4.85± 0.07(H2O,t=25±0.1,I=0.1(NaCl)) (Uncertain)
물리적 상태
가루
색상
흰색에서 황백색까지
생물학적 소스
synthetic (organic)
수용성
불용성
Merck
13 · 13,7968
BRN
5294062 · 5294062
안정성
1 · 제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°C에서 최대 1개월 동안 보관할 수 있습니다.
InChI
1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
InChIKey
GMVPRGQOIOIIMI-DWKJAMRDSA-N
SMILES
O=C1[C@H](CCCCCCC(O)=O)[C@@H](/C=C/[C@H](CCCCC)O)[C@H](O)C1

화학적 성질

Crystalline Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 74 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 3 (100%)

독성 정보

Adverse EffectsAdverse Effects of Intraurethral Alprostadil Suppositories (MUSE)
Toxicity Summary · 1건

The use of alprostadil for the treatment of erectile dysfunction in males may lead to prolonged erections and, in some cases, priapism. The incidence of priapism as an adverse effect of alprostadil is more common with the intraurethral suppository. This condition can also occur when unauthorized combination therapy is used or when patients exceed the prescribed dosage.

안전 데이터

wgk
3
rtecs
GY4569800
ridadr
UN 2811 6.1/PG 3
HS 번호
29375000
risk_code
22-36/37/38-61
hazard_code
Xn,Xi
safety_code
36-26
포장분류
III
위험 등급
6.1(b)
F 고인화성물질
8-10
Hazard Classifications
Acute Tox. 3 Oral
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

화학 및 산업

약리 정보

ATC Code · 5건

G04BE01

G - Genito urinary system and sex hormones

C - Cardiovascular system

QG - Genito urinary system and sex hormones

QC - Cardiovascular system

Protein BindingAlprostadil is bound in plasma primarily to albumin (81% bound) and, to a lesser extent, alpha-globulin IV-4 fraction (55% bound).
Pharmacodynamics · 1건

Prostaglandin E1 is produced endogenously to relax vascular smooth muscle and cause vasodilation. As a synthetic form of prostaglandin E1, alprostadil has the same pharmacodynamic effects. Alprostadil inhibits platelet aggregation, has anti-inflammatory effects, interferes with immune responses, and stimulates factor X, a blood coagulation enzyme. In adult males, the use of alprostadil may lead to prolonged erection and priapism, penile fibrosis, hypotension, and injection site bleeding. In patients treated up to 24 months with alprostadil, the incidence of prolonged erections (>4 hours long) was 4% of all, and the incidence of priapism (erections greater than 6 hours in duration) was <1%. Patients with preexisting cardiovascular disease treated with alprostadil may also have higher cardiac risk. Neonates with congenital heart defects treated with alprostadil may experience apnea. Apnea is experienced by 10-12% of neonates and is more common in those weighing less than 2 kg at birth. The administration of alprostadil to neonates may also result in gastric outlet obstruction secondary to antral hyperplasia.

Mechanism of Action · 1건

Alprostadil is a smooth muscle relaxant that promotes vasodilation and platelet aggregation inhibition. In neonatal patients with ductus arteriosus patency, alprostadil relaxes the ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. Alprostadil appears to be most effective within 96 hours after birth since the DA rapidly loses its responsiveness to alprostadil. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea leading to penile rigidity. This is referred to as the corporal veno-occlusive mechanism.

Biological Half-LifeIn healthy adults and neonates given a single intravenous dose of alprostadil, half-life goes from 5 to 10 minutes.
Metabolism/Metabolites · 1건

Alprostadil is rapidly metabolized in the human body. Following intracavernous administration, alprostadil is metabolized in the corpus cavernosum, and a smaller portion is absorbed from the penis into systemic circulation. After intravenous or arterial administration, alprostadil is metabolized and distributed throughout the entire body except for the central nervous system. As much as 60-90% of the circulating alprostadil may be metabolized in the lungs through first-pass pulmonary elimination, in a process known as beta- and omega-oxidation. The enzymatic oxidation of the C15-hydroxy group of alprostadil leads to the formation of 15-keto-PGE<sub>1</sub>, while the reduction of the C13, 14-double bond produces 15-keto-PGE<sub>0</sub>, and 13,14-dihydro-PGE<sub>1</sub> (PGE<sub>0</sub>). The 15-keto metabolites are inactive, but the PGE<sub>0</sub> metabolite has a similar potency to alprostadil in isolated animal organs. The major metabolite of alprostadil is 15-keto-PGE<sub>0</sub>.

FDA Pharmacological Classification · 6건

F5TD010360

ALPROSTADIL

Physiologic Effects [PE] - Genitourinary Arterial Vasodilation

Established Pharmacologic Class [EPC] - Prostaglandin Analog

Established Pharmacologic Class [EPC] - Prostaglandin E1 Agonist

Mechanisms of Action [MoA] - Prostaglandin Receptor Agonists

MeSH Pharmacological Classification · 3건

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Drugs used to cause dilation of the blood vessels.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

Absorption, Distribution and Excretion · 4건

In patients with erectile dysfunction given 20 μg of alprostadil intracavernously, the systemic plasma concentrations of prostaglandin E1 increased from a baseline of 0.8 pg/mL to a Cmax of 16.8 pg/mL (corrected for baseline). The tmax and AUC for this group of patients were 4.8 min and 173 pg⋅min/mL, respectively. In patients given 20 μg of alprostadil intravenously, AUC was similar to the one detected in patients that received alprostadil intracavernously (174 pg⋅min/mL); however, they had a higher tmax (25.5 min) and a lower Cmax (7.09 pg/mL). Compared to the same dose given by a short-term intravenous infusion, the absolute bioavailability of alprostadil estimated from systemic exposure was about 98%.

Following the degradation of alprostadil by beta- and omega-oxidation, metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration (92%). Approximately 88% and 12% of alprostadil metabolites are excreted through urine and feces, respectively, over 72 hours. Alprostadil and its metabolites are not retained in tissues, and unchanged alprostadil has not been detected in urine.

The volume of distribution of alprostadil has yet to be determined.

In patients with erectile dysfunction given an intravenous infusion of alprostadil (20 μg), the total body clearance was 115 L/min.

Tissue LocationsEpidermis
Cellular LocationsCytoplasm
응용 분야 · 5건

개요Alprostadil은 또한 노르 에피네프린의 신경 방출을 방지하여 노르 에피네프린의 혈관 수축 작용을 길항 할 수 있으며 비 아드레날린, 비 콜린성 혈관 확장 성 신경 전달 물질의 작용을 향상시킬 수 있습니다. ED 치료에서 알프로 스타 틸은 섬유주 평활근을 이완시키고 해면 동맥과 그 가지를 확장시킴으로써 발기를 유도합니다.

용도Alprostadil (Prostglandin E1)은 성인 남성의 발기 부전 (ED) 치료에 사용됩니다.

개요Prostaglandin E1 is an endogenous prostaglandin with vasodilatory, anti-platelet, and anti-hypertensive activities. It is in clinical use for the treatment of erectile dysfunction and the emergency management of infants with patent ductus arteriosus. It has also been used in the treatment of peripheral arterial occlusive disease (PAD).

용도A primary Prostaglandin; easily crystallized from purified biological extracts. Vasodilator (peripheral)

일반 설명PGE1, Alprostadil (Prostin VR Pediatric), is a naturally occurring prostaglandin that has found particular use in maintaining a patent (opened) ductus arteriosus in infants with congenital defects that restrict pulmonary or systemic blood flow. Alprostadil must be administered intravenously continually at a rate of approximately 0.1 μg/kg/min to maintain the patency of the ductus arteriosus until corrective surgery can be performed. Up to 80% of circulating alprostadil may be metabolized in a single pass through the lungs. Because apnea has been observed in 10% to 12% of neonates with congenital heart defects, this product should be administered only when ventilatory assistance is immediately available. Other commonly observed side effects include decreased arterial blood pressure, which should be monitored during infusion; inhibited platelet aggregation, which might aggravate bleeding tendencies; and diarrhea.

상·하류 제품 정보

상류 원료

2-N-BUTOXYETHYL메타크릴레이트질산 은gamma-Linolenic acid methyl ester글루타티온사이클로펜텐수소아라키돈산Prostaglandin E2Ethyl acetate solution나트륨 과요오드산모노에틸렌글리콜메틸산 나트륨p-토루엔 술폰산 일수화물포타슘터셔리부톡사이드수소화나트륨오스뮴산프로스타글란딘E1METHYLESTER(2R,3S)-1,2-Epoxy-3-hydroxy-4-pentene

관련 반응

18건
반응 기록 만들기
HRID 26304 반응식
HRID 26304반응물로
HRID 46949 반응식
HRID 46949반응물로
HRID 329226 반응식
HRID 329226반응물로
HRID 437096 반응식
HRID 437096반응물로
HRID 462132 반응식
HRID 462132반응물로
HRID 866499 반응식
HRID 866499반응물로
HRID 866500 반응식
HRID 866500반응물로
HRID 866665 반응식
HRID 866665반응물로
이전1 / 3 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트